Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924898 · ClinicalTrials.gov registry record · Phase 4
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT00924898 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 92 participants.
The verdict
NCT00924898, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1. To determine the safety and tolerability, and the virologic and immunologic efficacy of FTC, TDF, and efavirenz given once daily to patients with acute HIV infection. 2. To assess the impact of once daily therapy combined with a standardized adherence program on treatment adherence, virologic suppression, and rate of viral load decline in blood and infectious fluids (semen, cervico-vaginal secretions). 3. To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents among persons diagnosed with acute HIV infection in the Southeastern United States.
Interventions
- DRUG efavirenz, emtricitabine, and tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2005-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924898
The ClinicalTrials.gov registry entry for NCT00924898 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efavirenz, emtricitabine, and tenofovir is the first listed.
NCT00924898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924898 about?
NCT00924898 is a clinical study titled "Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)". This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1. To determine the safety and tolerability, and the virologic and immunologic efficacy of FTC, TDF, and efavirenz given once dail...
What is the current status of trial NCT00924898?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2005-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00924898?
The interventions under investigation include: efavirenz, emtricitabine, and tenofovir (DRUG).
Who is sponsoring clinical trial NCT00924898?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.